Table 3.
Clinical trials of anti-CD137 agonistic mAbs
| NCT number | Phase | Condition | Combination | Start year | Status (May 2015) |
|---|---|---|---|---|---|
| Urelumab (BMS-663513): fully human type IgG4, Bristol-Myers Squibb | |||||
| NCT00309023 | I/II | Metastatic or locally advanced solid tumors | – | 2005 | Terminated |
| NCT00351325 | I | Advanced solid malignancies | Chemotherapy | 2007 | Terminated |
| NCT00461110 | I | Non–small cell lung cancer | Chemoradiation | 2008 | Terminated |
| NCT00612664 | II | Melanoma | – | 2008 | Completed |
| NCT00803374 | I | Advanced malignant melanoma | Ipilimumab (anti–CTLA-4 mAb) | 2010 | Withdrawn |
| NCT01471210 | I | Advanced and/or metastatic solid tumors relapsed/refractory B-cell NHL | – | 2012 | Recruiting |
| NCT01775631 | Ib | Relapsed/refractory B-cell NHL | Rituximab (anti-CD20 mAb) | 2013 | Recruiting |
| NCT02110082 | Ib | Colorectal cancer, head and neck cancer | Cetuximab (anti-EGFR mAb) | 2014 | Recruiting |
| NCT02252263 | I | Multiple myeloma | Elotuzumab (anti-CS1 mAb) | 2014 | Recruiting |
| NCT02253992 | I/II | Advanced solid tumors, advanced B-cell NHL | Nivolumab (anti–PD-1 mAb) | 2014 | Recruiting |
| NCT02420938 | II | Relapsed/refractory/high-risk untreated chronic lymphocytic leukemia | Rituximab (anti-CD20 mAb) | 2015 | Not yet recruiting |
| PF-05082566: fully human type IgG2, Pfizer | |||||
| NCT01307267 | I | CD20-positive NHL | Rituximab (anti-CD20 mAb) | 2011 | Recruiting |
| NCT02179918 | Ib | Advanced solid tumors | MK-3475 (anti–PD-1 mAb) | 2014 | Recruiting |
Abbreviation: NHL, non-Hodgkin lymphoma.